Estrogenic compounds, including estrogens and selective estrogen receptor modulators (SERMs), have been proposed as adjunctive treatments for schizophrenia-spectrum disorders (SSD). Hormonal fluctuations have been associated with symptom exacerbation, antipsychotic response, and cognitive dysfunction, suggesting a possible therapeutic role for these agents.
However, clinical trial results have been mixed, with efficacy potentially moderated by factors such as dosage, treatment duration, sex, and menopausal status. A continuously updated synthesis is needed to evaluate the evolving evidence base.
“We hope that this living systematic review will bring rapid and much-needed clarity to one of the most intense debates in mental health today, informing scientists, policy-makers, parents, and young people themselves on the current state of evidence.” – Niall Boyce, Wellcome